{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:24:17Z","timestamp":1760189057111},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1991,11]]},"abstract":"<jats:title>Abstract.<\/jats:title>\n<jats:p>We measured thyrotropin receptor antibodies in serum obtained from 2 groups of patients participating in clinical trials of recombinant interferon-\u03b1 2b for viral hepatitis. Group I: Patients with hepatitis B (N=8), received interferon 5\u00d710<jats:sup>6<\/jats:sup> units thrice weekly for 4 months. Group II: Patients with non-A, non-B hepatitis (N=16) were randomized to receive interferon in a dose of either 0.25\u00d710<jats:sup>6<\/jats:sup> or 3\u00d710<jats:sup>6<\/jats:sup> U thrice weekly for 6 months and then crossed over to receive the other dosage schedule for a further 6 months. None of the patients developed thyrotoxicosis. Thyrotropin receptor antibody activity was detectable within the \"normal range\" (&lt;10 U\/l) in 6 patients prior to treatment. In Group I, thyrotropin receptor antibodies became detectable in 6 patients on treatment, in 4 of whom it was 10 U\/l. In Group II, thyrotropin receptor antibody activity was unchanged on low-dose interferon, but on the higher dose became detectable in 9 patients, in 7 of whom it was &gt;10 U\/l. We conclude that treatment with interferon is associated with the development of thyrotropin receptor antibodies in a large proportion of patients. It is possible that in some patients treated with higher doses of interferon the increase in thyrotropin receptor antibody activity may be sufficient to induce hyperthyroidism.<\/jats:p>","DOI":"10.1530\/acta.0.1250491","type":"journal-article","created":{"date-parts":[[2009,6,11]],"date-time":"2009-06-11T17:28:10Z","timestamp":1244741290000},"page":"491-493","update-policy":"http:\/\/dx.doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":11,"title":["Thyrotropin receptor antibodies following treatment with recombinant \u03b1-interferon in patients with hepatitis"],"prefix":"10.1093","volume":"125","author":[{"given":"V.","family":"Fonseca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Dusheiko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","container-title":["Acta Endocrinologica"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/125\/5\/acta_125_5_003.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/125\/5\/acta_125_5_003.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:13:48Z","timestamp":1676391228000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/125\/5\/491\/6769213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,11]]},"references-count":0,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.1530\/acta.0.1250491","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991,11]]}}}